Mein Warenkorb

Angiopoietin-2

Angiopoietin-2 Molekülinformation

Englischer NameAngiopoietin-2Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel12Target-AliasANGPT2,Angiopoietin 2,ANG-2,Angiopoietin-2B,Angiopoietin-2a,Angiopoietin-2,Tie2-Ligand,AGPT2,ANG2
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameAngiopoietin-2
Target-AliasANGPT2,Angiopoietin 2,ANG-2,Angiopoietin-2B,Angiopoietin-2a,Angiopoietin-2,Tie2-Ligand,AGPT2,ANG2
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel12
Höchste Forschungs- und EntwicklungsphaseApproved

Angiopoietin-2 Molekülhintergrund

Angiopoietin-2 is also known as ANGPT2, AGPT2, ANG2, and is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Ang2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel Palade bodies. Both Ang2 and the related Angiopoietin1 (Ang1) are ligands for the receptor tyrosine kinase Tie 2. Ang2 functions as a proangiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang2 is required for postnatal vascular remodeling, and it cooperates with Ang1 during lymphatic vessel development. It mediates the upregulation of ICAM1 and VCAM1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang2 competitively inhibit Ang1-induced endothelial cell responses mediated by Tie2, and reduces vascular integrity. But the role of Ang2 is controversial since the opposite outcomes has been reported in other studies. Over-expression of Ang2 disrupts the vascular remodeling, induce endothelial cell apoptosis, and may play an important regulating role in tumor angiogenesis. Ang2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.

Angiopoietin-2 Molekülalias

ANGPT2,AGPT2,ANG2,Angiopoietin-2

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
TrebananibAMG-386; 20060439Phase 2 ClinicalAmgen Inc, Takeda Pharmaceutical Co LtdAdenocarcinoma, Clear Cell; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Glioblastoma; Gliosarcoma; Hemangiosarcoma; Kidney Diseases; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Renal Insufficiency; Sarcoma; Sarcoma, Endometrial Stromal; Solid tumours; Uterine Neoplasms
Details
EXG102-031EXG102-031; EXG102-031 (rAAV-based gene therapy)Phase 2 ClinicalExegenesis Bio IncMacular Degeneration; Wet Macular Degeneration
Details
XMVA09XMVA-09; XMVA-09 (AAV载体基因治疗药物)Phase 2 ClinicalStarry GeneDiabetic macular oedema; Wet Macular Degeneration
Details
ASKG-712ASKG-712; AM-712; VIS-101Phase 2 ClinicalAskgene PharmaDiabetic macular oedema; Geographic Atrophy; Macular Degeneration; Wet Macular Degeneration
Details
Y-400Y-400Phase 2 ClinicalWuhan Yzy Biopharma Co LtdDiabetic macular oedema; Macular Degeneration; Wet Macular Degeneration
Details
ZifibancimigRO-7250284Phase 2 ClinicalF. Hoffmann-La Roche LtdMacular Degeneration
Details
BI-836880BI-836880Phase 2 ClinicalAblynx NvNeoplasms; Wet Macular Degeneration
Details
VanucizumabRG-7221; RO-5520985; B800Z06O8K (UNII code)Phase 1 ClinicalF. Hoffmann-La Roche LtdColorectal Neoplasms; Neoplasms; Solid tumours
Details
IBI-324IBI-324; OLN324Phase 1 ClinicalInnovent Biologics (Usa), IncDiabetic macular oedema; Macular Degeneration
Details
EB-105EB-105Phase 1 ClinicalEluminex Biosciences (Suzhou) LtdDiabetic macular oedema; Diabetic Retinopathy
Details
Bispecific antibody for ocular fundus(kexing)GB-10; GB10Phase 1 ClinicalShandong Kexing Bio-Products Co LtdEye Diseases; Macular Degeneration; Wet Macular Degeneration
Details
RG-6120RG-6120Phase 1 ClinicalF. Hoffmann-La Roche LtdMacular Degeneration
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
FaricimabRO-6867461; RG-7716ApprovedF. Hoffmann-La Roche Ltd, Genentech IncVabysmo, 罗视佳United StatesWet Macular Degeneration; Diabetic macular oedemaGenentech Inc2022-01-28Choroid Diseases; Choroidal Neovascularization; Diabetes Complications; Diabetes Mellitus; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Myopia; Polypoidal choroidal vasculopathy; Retinal Diseases; Retinal Vein Occlusion; Vision Disorders; Wet Macular Degeneration
Details

Produktrezensionen

  • C***r2023-04-25
    0Menschen mögen
    We purchased His tagged Mouse/ANGPT2 Protein to run plate-based functional assays with our large molecules. It performed better than some commercial reagents from other vendors in the ELISA assays.
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns